HCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)

Kim, W. R.Loomba, R.Berg, T.Schall, R. AguilarYee, L.Dinh, P.Flaherty, J. F.Martins, E. B.Jacobson, I.Fung, S.Gürel, S.Buti, M.Marcellin, P.2024-08-062024-08-062015-04-010168-8278https://www.sciencedirect.com/science/article/pii/S0168827815308497https://doi.org/10.1016/S0168-8278(15)30849-7https://hdl.handle.net/11452/43747Bu çalışma, 22-26, Nisan 2015 tarihlerinde Vienna[Avusturya]’da düzenlenen 50. International Liver Congress of the European-Association-for-the-Study-of-the-Liver Kongresi‘nde bildiri olarak sunulmuştur.eninfo:eu-repo/semantics/closedAccessGastroenterology & hepatologyHCC risk scores: Application of the CU-HCC, GAG-HCC and page-B scores to chronic hepatitis B (CHB) patients treated with tenofovir disoproxil fumarate (TDF)Meeting Abstract000362830600361S561S56162Supplement 210.1016/S0168-8278(15)30849-7